Immutep's Eftilagimod Alfa Secures FDA Orphan Drug Designation for Soft Tissue Sarcoma
IMMP has more than doubled off its 52-week low of $0.293.
Summary
Immutep has received FDA Orphan Drug Designation (ODD) for its lead product candidate, eftilagimod alfa (efti), for the treatment of Soft Tissue Sarcoma (STS). This designation is a significant regulatory milestone, offering benefits such as potential tax credits, fee exemptions, and seven years of market exclusivity upon approval, which can substantially de-risk development and enhance commercial prospects for this rare cancer. The ODD is supported by encouraging clinical data from the investigator-initiated Phase II EFTISARC-NEO trial, which met its primary endpoint with strong tumor response. While the company recently discontinued its Phase III TACTI-004 trial for efti in a different indication, this new positive development for STS provides a potential direct path to a late-stage study, according to the CEO. Investors will be watching for further updates on Immutep's strategic review and plans for advancing efti in STS.
At the time of this announcement, IMMP was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41M. The 52-week trading range was $0.29 to $3.53. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.